Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 (SUN101) in Subjects With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 May 2018
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary) ; Ipratropium bromide; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms GOLDEN-1
- Sponsors Sunovion Respiratory Development
- 22 May 2013 Tolerability results presented at the 109th International Conference of the American Thoracic Society.
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 03 Sep 2012 Results have been presented at the 2012 European Respiratory Society Annual Congress according to an Elevation Pharmaceuticals media release. Results were also reported in the media release.